SummaryWhat is known and objective: Proton pump inhibitor (PPI) prescribing may often be inappropriate and expose patients to a risk of adverse effects, while incurring unnecessary healthcare expenditure. Our objective was to determine PPI usage in Australia since 2002 and review international studies investigating inappropriate PPI prescribing, including those that discussed interventions to address this issue.
Methods: Australian Pharmaceutical Benefits Scheme (PBS) and RepatriationPharmaceutical Benefits Scheme (RPBS) data were analysed. A narrative literature review relevant to the objective was conducted. Time series analysis was also used to examine the trend of reported PPI appropriate use across the international studies included in this review.
Results and discussion
K E Y W O R D Sdeprescribing, gastro-oesophageal reflux, PPI, prescribing patterns, proton pump inhibitor